Also known as: TP-7
Selank is a synthetic anxiolytic peptide approved in Russia studied for reducing anxiety and improving mental clarity, with effects comparable to benzodiazepines but without sedation or dependence.
Modulates GABA/serotonin neurotransmitter systems. Enhances immune function by influencing IL-6 and T-helper cell balance. Stabilizes enkephalin levels.
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Selank (also known as TP-7) is a prominently researched experimental compound classified strictly within the Anxiolytic Peptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it modulates GABA/serotonin neurotransmitter systems. Enhances immune function by influencing IL-6 and T-helper cell balance. Stabilizes enkephalin levels. with a documented biological half-life of roughly 0.5 hours, In preclinical investigative trials and independent academic studies, researchers utilizing Selank have documented significant, quantifiable biological outcomes, primarily focusing on anxiety reduction, mental clarity, mood. Typical research protocols investigate administering 300 to 300mcg via nasal pathways 7x/wk. However, it is critically important to understand that while Selank demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
Modulates GABA/serotonin neurotransmitter systems. Enhances immune function by influencing IL-6 and T-helper cell balance. Stabilizes enkephalin levels.
Clinical trial demonstrates Selank's anxiolytic efficacy in patients with generalized anxiety disorder, comparable to benzodiazepines but without sedation or dependence.
ModerateStudy confirms Selank provides significant anti-anxiety effects comparable to benzodiazepine treatment, with added cognitive enhancement and no addictive potential.
ModerateSelank increases BDNF production in the rat hippocampus and prefrontal cortex, preventing ethanol-induced memory impairment and enhancing synaptic plasticity.
PreclinicalMolecular study showing Selank influences GABA-A receptor subunit gene expression, providing mechanism for its anxiolytic effects without sedation.
PreclinicalA study published in Frontiers in pharmacology investigating the effects and mechanisms.
PreclinicalA study published in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections investigating the effects and mechanisms.
PreclinicalA study published in Protein and peptide letters investigating the effects and mechanisms.
PreclinicalA study published in Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova investigating the effects and mechanisms.
PreclinicalA study published in Frontiers in pharmacology investigating the effects and mechanisms.
PreclinicalA study published in Molecular immunology investigating the effects and mechanisms.
PreclinicalVery safe profile. No reported dependence or withdrawal. Approved as anxiolytic in Russia. Not FDA-approved in US.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Nasal spray: 1-2 sprays per nostril. Non-addictive; can be used daily.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
Rapid reduction in anxiety within days; improved stress resilience; calmer baseline
Weeks 2–4
Stable anxiolytic effects without sedation; improved sleep onset
Month 2–3
Adaptive reduction in baseline anxiety; improved immune markers in some studies
Long-term
Effects generally require cycling; tolerance is low compared to benzodiazepines
| Side Effect | Incidence | Severity |
|---|---|---|
Mild fatigue | ~5% of users | mild |
Nasal irritation Intranasal route only | ~6% of users | mild |
Mood fluctuation | ~3% of users | mild |
Finding verified, high-purity Selank requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Selank✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
Dr. E. Vance
Editorial Director, PeptiDex
Dr. E. Vance is the Editorial Director at PeptiDex and leads the platform's editorial division, ensuring that every published research summary meets rigorous preclinical citation standards. With a Ph.D. in Molecular Pharmacology from Columbia Univers...
View Full Profile